A Study to Evaluate Convalescent Plasma to Stem Coronavirus

Overview

About this study


The purpose of this study is to assess the effectiveness and safety of Human coronavirus immune plasma (HCIP) to reduce the risk of hospitalization or death, the duration of symptoms and duration of nasopharyngeal or oropharyngeal viral shedding.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 18 years of age.
  • Competent and capable to provide informed consent.
  • Positive RNA test for presence of SARS-CoV-2 in fluid collected by oropharyngeal or nasopharyngeal swab.
  • Experiencing any symptoms of COVID-19 including but not limited to fever(T > 100.5º F), cough, or other COVID associated symptoms like anosmia.
  • ≤ 8 days since the first symptoms of COVID-19.
  • ≤ 8 days since first positive SARS-CoV-2 RNA test.
  • Able and willing to comply with protocol requirements listed in the informed consent.

Exclusion Criteria:

  • < 18 years of age.
  • Hospitalized or expected to be hospitalized within 24 hours of enrollment.
  • Psychiatric or cognitive illness or recreational drug/alcohol use that, in the opinion of the principal investigator, would affect subject safety and/or compliance.
  • History of prior reactions to transfusion blood products.
  • Inability to complete therapy with the study product within 24 hours after enrollment.
  • Receiving any treatment drug for COVID-19 within 14 days prior to screening like hydroxychloroquine, compassionate use or study trial related).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Janis Blair, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions